Literature DB >> 19442162

Neutralizing endogenous VEGF following traumatic spinal cord injury modulates microvascular plasticity but not tissue sparing or functional recovery.

Richard L Benton1, Melissa A Maddie, Mark J Gruenthal, Theo Hagg, Scott R Whittemore.   

Abstract

Acute loss of spinal cord vascularity followed by an endogenous adaptive angiogenic response with concomitant microvascular dysfunction is a hallmark of traumatic spinal cord injury (SCI). Recently, the potent vasoactive factor vascular endothelial growth factor (VEGF) has received much attention as a putative therapeutic for the treatment of various neurodegenerative disorders, including SCI. Exogenous VEGF exerts both protective and destabilizing effects on microvascular elements and tissue following SCI but the role of endogenous VEGF is unclear. In the present study, we systemically applied a potent and well characterized soluble VEGF antagonist to adult C57Bl/6 mice post-SCI to elucidate the relative contribution of VEGF on the acute evolving microvascular response and its impact on functional recovery. While the VEGF Trap did not alter vascular density in the injury epicenter or penumbra, an overall increase in the number of Griffonia simplicifolia isolectin-B4 bound microvessels was observed, suggesting a VEGF-dependency to more subtle aspects of endothelial plasticity post-SCI. Neutralizing endogenous VEGF neither attenuated nor exacerbated chronic histopathology or functional recovery. These results support the idea that overall, endogenous VEGF is not neuroprotective or detrimental following traumatic SCI. Furthermore, they suggest that angiogenesis in traumatically injured spinal tissue is regulated by multiple effectors and is not limited by endogenous VEGF activation of affected spinal microvessels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442162      PMCID: PMC2813492          DOI: 10.2174/156720209788185678

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  54 in total

1.  Genes expressed in human tumor endothelium.

Authors:  B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

2.  New vascular tissue rapidly replaces neural parenchyma and vessels destroyed by a contusion injury to the rat spinal cord.

Authors:  Gizelda T B Casella; Alexander Marcillo; Mary Bartlett Bunge; Patrick M Wood
Journal:  Exp Neurol       Date:  2002-01       Impact factor: 5.330

3.  Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration.

Authors:  M Sköld; S Cullheim; H Hammarberg; F Piehl; A Suneson; S Lake; A Sjögren; E Walum; M Risling
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

4.  Cyclosporin A treatment following spinal cord injury to the rat: behavioral effects and stereological assessment of tissue sparing.

Authors:  A G Rabchevsky; I Fugaccia; P G Sullivan; S W Scheff
Journal:  J Neurotrauma       Date:  2001-05       Impact factor: 5.269

5.  Temporal progression of angiogenesis and basal lamina deposition after contusive spinal cord injury in the adult rat.

Authors:  David N Loy; Charles H Crawford; Jessica B Darnall; Darlene A Burke; Stephen M Onifer; Scott R Whittemore
Journal:  J Comp Neurol       Date:  2002-04-15       Impact factor: 3.215

6.  Blood-spinal cord barrier after spinal cord injury: relation to revascularization and wound healing.

Authors:  William D Whetstone; Jung-Yu C Hsu; Manuel Eisenberg; Zena Werb; Linda J Noble-Haeusslein
Journal:  J Neurosci Res       Date:  2003-10-15       Impact factor: 4.164

7.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

8.  Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury.

Authors:  J Widenfalk; A Lipson; M Jubran; C Hofstetter; T Ebendal; Y Cao; L Olson
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Structural mechanisms of acute VEGF effect on microvessel permeability.

Authors:  Bingmei M Fu; Shang Shen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01-30       Impact factor: 4.733

10.  VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

Authors:  Yoshitsugu Saishin; Yumiko Saishin; Kyoichi Takahashi; Raquel Lima e Silva; Donna Hylton; John S Rudge; Stanley J Wiegand; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2003-05       Impact factor: 6.384

View more
  10 in total

1.  Vascular Pathology as a Potential Therapeutic Target in SCI.

Authors:  Richard L Benton; Theo Hagg
Journal:  Transl Stroke Res       Date:  2011-11-29       Impact factor: 6.829

Review 2.  State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.

Authors:  Evan Paul Tracy; Virginia Stielberg; Gabrielle Rowe; Daniel Benson; Sara S Nunes; James B Hoying; Walter Lee Murfee; Amanda Jo LeBlanc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

3.  Deficiency in matrix metalloproteinase-2 results in long-term vascular instability and regression in the injured mouse spinal cord.

Authors:  Alpa Trivedi; Haoqian Zhang; Adanma Ekeledo; Sangmi Lee; Zena Werb; Giles W Plant; Linda J Noble-Haeusslein
Journal:  Exp Neurol       Date:  2016-07-25       Impact factor: 5.330

4.  Bosentan protects the spinal cord from ischemia reperfusion injury in rats through vascular endothelial growth factor receptors.

Authors:  S Gong; Z Seng; W Wang; J Lv; Q Dong; B Yan; L Peng; X He
Journal:  Spinal Cord       Date:  2014-09-02       Impact factor: 2.772

5.  Multi-targeted neuroprotection by the HSV-2 gene ICP10PK includes robust bystander activity through PI3-K/Akt and/or MEK/ERK-dependent neuronal release of vascular endothelial growth factor and fractalkine.

Authors:  Jennifer M Laing; Cynthia C Smith; Laure Aurelian
Journal:  J Neurochem       Date:  2009-11-05       Impact factor: 5.372

Review 6.  A perspective on the role of class III semaphorin signaling in central nervous system trauma.

Authors:  Vasil Mecollari; Bart Nieuwenhuis; Joost Verhaagen
Journal:  Front Cell Neurosci       Date:  2014-10-27       Impact factor: 5.505

7.  Electroacupuncture improves microcirculation and neuronal morphology in the spinal cord of a rat model of intervertebral disc extrusion.

Authors:  Dai-Xun Jiang; Zhi-Song Lu; Ge-Bin Li; Sheng-Yong Sun; Xiang Mu; Peter Lee; Wu Chen
Journal:  Neural Regen Res       Date:  2015-02       Impact factor: 5.135

Review 8.  The Role of Biomaterials as Angiogenic Modulators of Spinal Cord Injury: Mimetics of the Spinal Cord, Cell and Angiogenic Factor Delivery Agents.

Authors:  Luís A Rocha; Rui A Sousa; David A Learmonth; António J Salgado
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

9.  Innovative mouse model mimicking human-like features of spinal cord injury: efficacy of Docosahexaenoic acid on acute and chronic phases.

Authors:  Sara Marinelli; Valentina Vacca; Federica De Angelis; Luisa Pieroni; Tiziana Orsini; Chiara Parisi; Marzia Soligo; Virginia Protto; Luigi Manni; Roberto Guerrieri; Flaminia Pavone
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

10.  The effect of 808 nm and 905 nm wavelength light on recovery after spinal cord injury.

Authors:  Barbora Svobodova; Anna Kloudova; Jiri Ruzicka; Ludmila Kajtmanova; Leos Navratil; Radek Sedlacek; Tomas Suchy; Meena Jhanwar-Uniyal; Pavla Jendelova; Lucia Machova Urdzikova
Journal:  Sci Rep       Date:  2019-05-21       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.